
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd Inc. is positioned favorably within the biopharmaceutical sector, leveraging its innovative antibody technologies to address infectious diseases with pandemic potential, particularly COVID-19. The company is developing advanced product candidates such as ADG20 and VYD222, which exhibit superior antiviral potency and broad neutralization capabilities, anticipated to enhance their marketability in a projected $3-4 billion global market by 2030. Furthermore, promising results from Phase 1/2 trials indicate a robust safety profile, instilling confidence in the efficacy and longevity of Invivyd’s products, which could serve as significant drivers of long-term growth.
Bears say
Invivyd Inc, while promoting innovative antibody solutions aimed at enhancing immune response against viruses like COVID-19, faces significant challenges regarding the efficacy and public acceptance of existing vaccines. The company's emphasis on the limitations of current vaccination approaches, including waning antibody responses and public hesitancy, illustrates a potential barrier to market penetration for its products. Despite a projected $4 billion in COVID vaccine revenue highlighting the total addressable market, this figure does not mitigate concerns regarding Invivyd's ability to distinguish its offerings or achieve sustained demand in a competitive and evolving landscape.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares